SCHEMBL210412

SCHEMBL210412

Cc1nc(C(=O)N(C)N(C)C)sc1-c1ccnc(NCc2ccc(C(=O)O)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.44
CDK4 P11802 5/20 0.44
AURKA O14965 2/20 0.44
CDK1 P06493 2/20 0.44
CDK7 P50613 2/20 0.44
CDK9 P50750 2/20 0.44
AURKB Q96GD4 2/20 0.44
VCP P55072 1/20 0.42
HDAC1 Q13547 8/20 0.40
HDAC3 O15379 1/20 0.40
NCOR1 O75376 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
CLK1 P49759 1/20 0.38
CCNE1 P24864 2/20 0.37
PIK3CA P42336 1/20 0.37
PLK1 P53350 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210411 0.86 CDK2 (0.46) CDK2CDK4AURKACDK1CDK7
SCHEMBL27589595 0.84 CDK2 (0.54) CDK2CDK4AURKACDK1CDK7
SCHEMBL210175 0.82 CDK4 (0.54) CDK2CDK4AURKACDK1CDK7
SCHEMBL211981 0.75 PI4KB (0.50) CDK2CDK4AURKACDK1CDK7
SCHEMBL2732947 0.72 HDAC1 (0.62) HDAC1HDAC3NCOR1HDAC2HDAC8
SCHEMBL16408476 0.71 VCP (0.59) AURKAVCPHDAC1HDAC3NCOR1
SCHEMBL27589593 0.71 CDK2 (0.49) CDK2CDK4AURKACDK1CDK7
SCHEMBL27578957 0.71 CDK2 (0.49) CDK2CDK4AURKACDK1CDK7
SCHEMBL211964 0.69 GPR39 (0.54) VCPHDAC1HDAC3NCOR1HDAC2
SCHEMBL27571295 0.69 CDK2 (0.49) CDK2CDK4AURKACDK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 CDK2 116/4885CDK4 76/4885AURKA 257/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 CDK2 72/4885CDK4 41/4885AURKA 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.